NEW YORK (GenomeWeb News) - Sentigen Holding today said that its stockholders have approved its planned merger with Invitrogen.
Sentigen said it expects the deal to close “within the next several weeks.”
As GenomeWeb News reported in August, Invitrogen said it planned to acquire Sentigen, which includes its subsidiaries Sentigen Biosciences and Cell & Molecular Technologies for
For around $25.9 million.